8-KItem 2.02 · Results of OperationsItem 9.01 · Financial Statements
Gilead reports 10% revenue growth but widens 2026 loss guidance
Filed with the SEC on · Summarized by InvestorsBot
Gilead’s second-quarter 2026 revenue rose 10% year over year to $7.8 billion, led by HIV sales up 12% to $5.7 billion and Biktarvy sales up 7% to $3.8 billion, while GAAP diluted loss was $8.45 per share after $11.2 billion of acquired in-process research and development expenses tied mainly to acquisitions of Arcellx, Tubulis and Ouro Medicines. For full-year 2026, Gilead raised product-sales guidance excluding Veklury to $29.8 billion-$30.1 billion but lowered GAAP loss-per-share guidance to $(3.75)-$(3.40); cash, cash equivalents and marketable debt securities fell to $3.2 billion as of June 30 after $11.3 billion in year-to-date acquisition spending.